COVID-19 can have a significant impact on liver besides respiratory and other vital systems, a study by a civic-run hospital here has shown.
The study by the Gastroenterology department of BYL Nair Hospital, which was among the main hospitals earmarked for treating coronavirus patients in the city, found that almost half the participants had developed liver abnormalities.
The report was recently published in the Indian Journal of Medical Research, a publication of the Indian Council of Medical Research. As many as 46 per cent of patients (who took part in the study) had liver abnormalities caused by coronavirus, overuse of experimental and potentially dangerous drugs early in the pandemic and critically low oxygen levels, it said. "The study findings have underlined that the liver also took a huge hit due to COVID-19, like the lungs and heart," said Dr Pravin Rathi, gastroenterologist and dean of Nair Hospital. Dr Sanjay Chandnani, a gastroenterologist and assistant professor at the hospital, told PTI that of 3,280 patients admitted in their COVID-19 center, around 1,500 patients above 18 years of age were examined during the study. COVID-19 was known to affect respiratory, gastrointestinal, cardiovascular and other systems, but there were very few studies describing liver involvement and liver function test (LFT) abnormalities, he said. The study at Nair Hospital revealed that as the severity of COVID-19 infection increases, liver function abnormalities worsen, and such patients are more likely to develop a severe disease. "In COVID-19, LFT abnormalities were common, and derangement increased as severity progressed. The presence of deranged LFT worsens the clinical outcome and predicts high risk of deaths in hospitalised patients," the report read. "The cause of derangement is multifactorial. It could be due to virus itself, multiple drugs, complimentary and ayurvedic medications, low oxygen levels and any pre-existing liver disease," Dr Chandnani said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app